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Abstract
Background: Cancers of Unknown Primary (CUP) are the 3-4th most common causes of cancer death and recent
clinical guidelines recommend that patients should be directed to a team dedicated to their care. Our aim was to
inform the care of patients diagnosed with CUP during hospital admission.
Methods: Descriptive study using hospital admissions (Scottish Morbidity Record 01) linked to cancer registrations
(ICD-10 C77-80) and death records from 1998 to 2011 in West of Scotland, UK (population 2.4 m). Cox proportional
hazards models were used to assess effects of baseline variables on survival.
Results: Seven thousand five hundred ninety nine patients were diagnosed with CUP over the study period, 54.4%
female, 67.4% aged ≥ 70 years, 36.7% from the most deprived socio-economic quintile. 71% of all diagnoses were
made during a hospital admission, among which 88.6% were emergency presentations and the majority (56.3%)
were admitted to general medicine. Median length of stay was 15 days and median survival after admission
33 days. Non-specific morphology, emergency admission, age over 60 years, male sex and admission to geriatric
medicine were all associated with poorer survival in adjusted analysis.
Conclusions: Patients with a diagnosis of CUP are usually diagnosed during unplanned hospital admissions and
have very poor survival. To ensure that patients with CUP are quickly identified and directed to optimal care,
increased surveillance and rapid referral pathways will be required.
Keywords: Occult primary neoplasms, Unknown primary tumor
Background
Cancers of unknown primary (CUP) are metastatic ma-
lignancies for which a primary site has not been identi-
fied [1]. They are therefore a disparate group of cancers
that present at an advanced stage. The incidence of CUP
has risen and then fallen over the past 50 years, [2–5]
possibly driven initially by greater diagnostic sensitivity
detecting more metastatic disease and then latterly by
better identification of the primary site reducing the
number of unknown primaries. Worldwide, CUP are the
6th to 8th most common cancers, accounting for 2.3–5%
of all cancer diagnoses but the 3rd to 4th most common
cause of death from cancer [6, 7]. They comprised 3.2%
of all invasive cancers in Scotland between 2001 and
2010 [7]. They were responsible for 7% of United
Kingdom (UK) cancer deaths in 2009 [8]. Survival is
poor, with a median of 5.6 weeks [7]. Survival is more
favourable among patients whose disease mimics clinico-
pathological features of known metastatic cancers and
responds to appropriate treatment (median survival
24 months) but the majority of patients (80–85%) re-
spond poorly to treatment [6].
In the United Kingdom, The National Institute for
Health and Care Excellence (NICE) issued a guideline
on CUP in 2010 [1]. Its recommendations included that
every hospital with a cancer centre should have a dedi-
cated CUP team and that investigations and manage-
ment be the responsibility of that team. The guideline is
currently on NICE’s static list, indicating that no new
evidence has become available. The European Society
for Medical Oncology (ESMO) issued clinical practice
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guidelines the following year, emphasising the need to
identify those patients with more favourable prognoses
so that they might benefit if directed to appropriate
multidisciplinary care [9]. The National Cancer
Intelligence Network reported on routes to diagnosis of
CUP between 2006 and 2010 [10]. They reported that
diagnoses were 20% higher among females, nearly 40%
were over 80 years old and 57% were diagnosed after an
emergency hospital admission. However, there is a pau-
city of evidence on patterns of hospital care for patients
with CUP and therefore on the capacity to better iden-
tify patients so that they might be directed to specialist
teams.
In order to inform the care of patients diagnosed with
CUP during hospital admission, we carried out a de-
scriptive study of all patients diagnosed over the most
recent 14-year period for which data were available,




The West of Scotland comprises approximately 2.4 mil-
lion residents, or just over half of the population of
Scotland. All residents can access National Health
Service hospitals, which are funded through general tax-
ation and care is free at the point of use. There were
about 10 acute hospitals in the region over the period of
this study with some opening and some closing. The re-
gion includes both urban and rural areas, with Glasgow
being the largest city (population approx 600,000). All
registrations for Cancer of Unknown Primary (Inter-
national Classification of Diseases (ICD) Revision 10
codes C77-C80) for the region were extracted from the
Scottish Cancer Registry for the period January 1998 to
December 2011 inclusive. Scottish cancer registrations
(Scottish Morbidity Record (SMR) number 6, SMR06)
are routinely linked to each individual’s acute hospital
records (SMR01) and death records; we obtained all
such linked records. The date range was chosen because
of enhanced information available from SMR01 from
1998 onwards. ICD-O (International Classification of
Diseases for Oncology) morphology codes were grouped
into four categories: not otherwise specified (NOS)
M8000/0-8046/6, squamous cell carcinoma (SCC)
M8050/0-8084/6, adenocarcinoma M8140/0-8420/6 and
“other” comprising all remaining morphological types.
ICD-O revisions 2 and 3 morphology classifications were
used for their appropriate time periods [11].
Socio-economic characteristics of patients were
assigned using the Scottish Index of Multiple
Deprivation (SIMD) [12]. This uses seven domains of
deprivation (income, employment, education, health, ac-
cess to services, crime and housing) to rank small
geographic areas in Scotland from least deprived to most
deprived. These have been grouped into national quin-
tiles from 1 (most deprived) to 5 (least deprived).
Statistical methods
Survival analysis
Survival analysis was performed on all incident cases
from 1998 to 2011 diagnosed during hospital admission
with survival time defined from diagnosis to death from
any cause. A censor date of 31st March 2013, the most
recent time-point for which complete vital status data
was available, was applied. Univariate survival analyses
were carried out using log rank tests and the assumption
of proportionality assessed by proportionality tests and
log-minus-log plots. For multivariate Cox proportional
hazards models, we used a forward stepwise approach,
entering demographic variables (age, sex) and then all
other variables found to be significant in log rank tests.
Statistical analysis was performed using Stata v13
(STATA Corp, College Station, TX, USA).
Results
7,599 diagnoses of CUP were made in the West of
Scotland between 1998 and 2011. Table 1 summarises
the demographics, ICD-10 site and morphology classifi-
cations of these diagnoses. Median age at incidence was
73 years in males and 77 years in females. Patients aged
over 70 years accounted for 67.4% of incident cases. The
crude rate of diagnoses averaged 18.14 per 100,000 per-
sons between 2008 & 2010.
A socioeconomic gradient was present, with 36.7% of
cases from the most deprived SIMD quintile versus
11.4% of cases from the least deprived quintile. The
most common ICD-10 site codes were C78 (secondary
malignant neoplasm of respiratory and digestive organs)
at 44.6% and C80 (malignant neoplasm, without specifi-
cation of site) at 33.3%.
Not otherwise specified (NOS) morphology accounted
for 67% of all incidences, adenocarcinomas for 24.8%,
SCC for 4.3% and all others 3.8%. Morphology varied by
age. Increasing age was associated with increased NOS
morphology, comprising 82.2% in patients aged 80 years
and older (Χ2 = 706, df = 9, p <0.001). SCC, adenocarcin-
oma and other morphologies had greatest proportions in
under-60 year-olds, their proportions decreasing with as-
cending age.
Patterns of hospital admission
Between 1998 and 2011, 5,397 incident cases of CUP
(71% of all CUP diagnoses in the period) were diagnosed
during hospital admission. Table 2 summarises patterns
of admission. Numbers declined over time, falling by an
annual mean of 29.6% between 1998–2002 and 2008–11.
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Most patients (88.6%) were admitted as emergen-
cies. Emergency admissions were older than elective
admissions (median ages 76 and 73 years, respect-
ively, Wilcoxon rank-sum p <0.001). Of patients
>80 years, 91.7% were admitted as emergencies com-
pared to 81.3% of those aged < 60 years (Pearson χ2
76.9363, p <0.001). The proportion of emergency
admissions increased over time from 86.5% in 1998–
2002–90.6% in 2008–2011 (χ2 17.4819, p <0.001). The
proportions of patients admitted to general medicine
increased over time from 54.4% in 1998–2002–60.3%
in 2008–2011 (χ2 16.1543, p = 0.013). Half of patients
(49.3%) died during their hospital stay; this was
higher (52.5%) for those who had an emergency ad-
mission (p < 0.001). The median length of stay was
15 days, with 21% of patients having a hospital stay
of 31 days or more.
Survival analysis
All incident cases of CUP diagnosed during hospital ad-
mission were included in survival analysis. Median sur-
vival was 33 days. One year survival was 6.2%; five year
survival was 1.4%.
Unadjusted survival analysis showed progressively
poorer outcomes with increasing age, such that hazards
of death at ≥ 80 years were twice that of those aged
under 60 (HR 1.94, 95% CI 1.77 to 2.14) – Table 3.
Increasing age was associated with poorer survival (P <
0.001). Median survival in the most deprived quintile
(33 days) was significantly poorer than in the least de-
prived (36 days, P < 0.001) but was not significantly differ-
ent from the other socio-economic quintiles. There was a
significant association between ICD-10 site and survival
(P <0.001); ICD-10 site C77 (Secondary and unspecified
malignant neoplasm of lymph nodes of head, face and
Table 1 Cancer of Unknown Primary patient characteristics, 1998–2011, West of Scotland. N = 7599
1998–2002 2003–2007 2008–2011 Total
N Col % N Col % N Col % N Col %
Total 3155 (100) 2669 (100) 1775 (100) 7599 (100)
Sex
Male 1480 (46.9) 1219 (45.7) 768 (43.3) 3467 (45.6)
Female 1675 (53.1) 1450 (54.3) 1007 (56.7) 4132 (54.4)
3155 (100) 2669 (100) 1775 (100) 7599 (100)
Age_group
< 60 year 434 (13.8) 313 (11.7) 244 (13.7) 991) (13.0)
60–69 years 647 (20.5) 507 (19.0) 328 (18.5) 1482 (19.5)
70–79 years 1124 (35.6) 899 (33.7) 569 (32.1) 2592 (34.1)
> =80 year 950 (30.1) 950 (35.6) 634 (35.7) 2534 (33.3)
SIMD
Most deprived 1170 (37.1) 976 (36.6) 643 (36.2) 2789 (36.7)
2 800 (25.4) 655 (24.5) 406 (22.9) 1861 (24.5)
3 462 (14.6) 428 (16) 304 (17.1) 1194 (15.7)
4 401 (12.7) 291 (10.9) 195 (11.0) 887 (11.7)
Least deprived 322 (10.2) 319 (12.0) 227 (12.8) 868 (11.4)
ICD10_site
C77 149 (4.7) 128 (4.8) 117 (6.6) 394 (5.2)
C78 1566 (49.6) 1163 (43.6) 661 (37.2) 3390 (44.6)
C79 608 (19.3) 433 (16.2) 241 (13.6) 1282 (16.9)
C80 832 (26.4) 945 (35.4) 756 (42.6) 2533 (33.3)
Morphology
Adenocarcinoma 880 (27.9) 615 (23.0) 390 (22.0) 1885 (24.8)
SCC 122 (3.9) 113 (4.2) 95 (5.4) 330 (4.3)
NoS 2039 (64.6) 1853 (69.4) 1201 (67.7) 5093 (67.0)
Other 114 (3.6) 88 (3.3) 89 (5) 291 (3.8)
N number of patients, Col % column percentage, SIMD Scottish Index of Multiple Deprivation, ICD10_site International Classification of Diseases, 10th Revision,
anatomical site, SCC squamous cell carcinoma, NoS not otherwise specified, C77 secondary and unspecified malignant neoplasm of lymph nodes, C78 secondary
malignant neoplasm of respiratory and digestive organs, C79 secondary malignant neoplasm of other sites, C80 malignant neoplasm without specification of site
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neck) had longest median survival (71 days) compared
with C79 (secondary malignant neoplasm of other sites) at
53 days. Sites 78 and C80 (secondary malignant neoplasm
of lung and malignant neoplasm without specification of
site, respectively) had similar median survival at 29 &
28 days respectively. Morphology was also significantly as-
sociated with survival (P <0.001); SCC had the longest sur-
vival (median 89 days); NOS had the poorest survival
(median 26 days). Emergency admissions had poorer sur-
vival than elective admissions, with median survivals of 30
and 75 days, respectively (P <0.001). Patients who were ad-
mitted to geriatric medicine wards had the poorest sur-
vival, (median 28 days) while admissions to “other”
specialties had the longest median survival (44 days).
There was no significant association between sex and
survival.
Table 4 summarises a multivariate analysis of survival.
The largest effect on survival was site, followed by
morphology, type of admission, age, sex and speciality of
admission. Deprivation was not significant once morph-
ology, type of admission, age, sex and speciality were in
the model.
Discussion
In a large population-based series of patients with Cancers
of Unknown Primary, we found that the majority were di-
agnosed during a hospital admission, half of whom died
during that admission. Survival after admission was short,
being a median of 33 days and poorer in emergency com-
pared to elective admissions. Median age was 75 years.
Survival in our study was less than the median 2–3
months reported by others [2–5, 10]. This may reflect
that patients in our study were diagnosed during a hos-
pital admission and may therefore have more advanced
CUP or other morbidities requiring admission. We also
found that a considerably smaller proportion of pa-
tients survived 5 years compared with others’ obser-
vations [2–5]. Long-term survivors are considered as
belonging to a favourable prognostic subset, who re-
spond to treatment for a primary cancer that CUP
appears to mimic [6]. Research into treatment regi-
mens is increasing for patients in both unfavourable
and favourable prognostic subsets; the ability to iden-
tify those most likely to benefit from these treatments
is important. Despite this, those in the unfavourable
prognostic subset have limited treatment options,
realistic aims being modest prolongation of life and
symptom relief [9].
Younger patients who were admitted electively have
the best survival from CUP. This is consistent with
demographic prognostic indicators noted previously.
This raises questions of whether physiological or
pathological processes can explain the development of
CUP; newer genetic profiling and imaging techniques
are being used to try to clarify the underlying physio-
logical and pathological processes in CUP develop-
ment. Inequity regarding treatment by sex, age and
deprivation is unlikely as currently there are no
proven treatments for patients belonging to the un-
favourable prognostic subset.
Table 2 Hospital admission characteristics and length of stay. Cancer of Unknown Primary diagnosed during hospital admission,
1998–2011, West of Scotland, N = 5397. p for Pearson’s chi-square test
1998–2002 2003–2007 2008–2011 Total p
N Col % N Col % N Col % N Col %
Total 2212 (100) 1939 (100) 1246 (100) 5397 (100)
Type of admission
Elective 299 (13.5) 201 (10.4) 117 (9.4) 617 (11.4)
Emergency 1913 (86.5) 1738 (89.6) 1129 (90.6) 4780 (88.6) <0.001
Specialty of admission
Geriatric medicine 258 (11.7) 222 (11.4) 124 (10) 604 (11.2)
Medicine 1203 (54.4) 1083 (55.9) 751 (60.3) 3037 (56.3)
Surgery 685 (31.0) 588 (30.3) 329 (26.4) 1602 (29.7)
Other 66 (3.0) 46 (2.4) 42 (3.4) 154 (2.9) 0.013
days in hospital
1–7 days 500 (22.0) 450 (22.7) 340 (26.4) 1290 (23.3)
8–14 days 548 (24.1) 429 (21.6) 284 (22) 1261 (22.7)
15–30 days 701 (30.9) 618 (31.1) 362 (28.1) 1681 (30.3)
31+ days 463 (20.4) 442 (22.3) 260 (20.2) 1165 (21.0) 0.016
N number of patients, Col % column percentage
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The increased risk of death in patients admitted to
geriatric medicine in multivariate analysis despite adjust-
ment for factors including age, sex, admission type and
CUP site and morphology codes is interesting and the
underlying reasons have not been determined. These pa-
tients may be more frail or have multiple comorbidities.
It is unlikely that their increased risk of death is due to
treatment because, as previously discussed, currently
treatment options are limited and unlikely to signifi-
cantly improve survival. We found that survival
appeared better for ICD-10 C77 and “other” morpholo-
gies. It is probable that some lymph node metastases
(C77) will represent regional rather than distant spread
which may explain their better survival on average. Fur-
ther research may be possible to better understand
whether particular morphological “other” groups are as-
sociated with better survival but numbers may be small.
We found that the morphology was coded as cancer
“not otherwise specified” (NOS) in 67% of all CUP inci-
dences. We anticipate that this was most commonly
Table 3 Survival of Cancer of Unknown Primary patients by demographic and clinical characteristics. Patients diagnosed during
hospital admission, 1998–2011, West of Scotland, N = 5397
median survival (days) HR (95% confidence interval) P-value
Gender
Male 32 1
Female 34 0.95 (0.90,1.00) 0.063
Age group
< 60 year 60 1
60–69 years 38 1.41 (1.27,1.56) <0.001
70–79 years 31 1.76 (1.60,1.93) <0.001
> = 80 year 27 1.94 (1.77,2.14) <0.001
SIMD
1. Most deprived 33 1
2 32 0.98 (0.91,1.05) 0.533
3 33 0.98 (0.90,1.06) 0.618
4 33 0.96 (0.88,1.06) 0.445
5. least deprived 36 0.83 (0.75,0.91) <0.001
ICD10_site
C77 71 1
C78 29 2.21 (1.86,2.63) <0.001
C79 53 1.49 (1.25,1.79) <0.001
C80 28 2.27 (1.91,2.71) <0.001
Morphology
Adenocarcinoma 48 1
SCC 89 0.63 (0.52,0.76) <0.001
NoS 26 1.53 (1.44,1.64) <0.001
Other 84 0.61 (0.51,0.72) <0.001
Type of admission <0.001
Elective 75 1
Emergency 30 1.88 (1.72,2.06) <0.001
Specialty of admission <0.001
Geriatric medicine 28 1
Medicine 30 0.87 (0.79,0.95) 0.002
Surgery 40 0.66 (0.60,0.73) <0.001
Other 44 0.52 (0.43,0.63) <0.001
SIMD Scottish Index of Multiple Deprivation, ICD10_site International Classification of Diseases, 10th Revision, anatomical site, SCC squamous cell carcinoma, NoS
not otherwise specified, HR hazard ratio, C77 secondary and unspecified malignant neoplasm of lymph nodes, C78 secondary malignant neoplasm of respiratory
and digestive organs, C79 secondary malignant neoplasm of other sites, C80 malignant neoplasm without specification of site
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because biopsy and microscopic assessment (i.e. patho-
logical confirmation) have not been undertaken, often
because this would not influence patient management
and/or because of the patient’s poor performance status.
In Brewster’s previous study of CUP in the Scottish
population between 2001 and 2010, 58% of CUP cases
were recorded as not microscopically verified [7]. We
anticipate that a proportion of incidences coded as can-
cer NOS will have shown a poorly differentiated tumour,
preventing more detailed cancer typing and sub-typing.
Given the poor outcomes of patients admitted to hos-
pital with CUP, is there scope for better primary and sec-
ondary prevention? Current understanding of the
underlying biology and pathogenesis of CUP is
incomplete [13]; therefore, the possibility of detecting
CUP earlier is uncertain. Unlike other cancers, for ex-
ample ovarian, rather than following a type 1 progres-
sion (from a pre-malignant to malignant lesion) it may
be malignant from the start – that is, type 2 progression
[6, 14]. Furthermore, the heterogeneity of CUP - its oc-
currence at any site as a variety of histological morph-
ologies - does not lend it to a simple and acceptable
method for early detection. Heterogeneity also results in
a wide range of signs and symptoms, making it a poor
candidate for a public health education campaign aiming
to increase awareness of potential signs and symptoms
of cancer and encourage primary care consultation. An
issue with this health awareness approach in patients
with CUP is that late presentation is often due to the
lack of symptoms until advanced stages of the disease
rather than failure to present to health services amongst
symptomatic patients. There is evidence of CUP cluster-
ing in families where a sibling has experienced CUP,
colorectal, hepatic, breast, ovarian, lung and renal can-
cers; suggesting a genetic basis to development of CUP,
an area for future research, which may aid earlier detec-
tion and prevention of CUP [15].
Our study has strengths and weaknesses. Its strengths
include the use of high quality cancer registry data and
linkage to comprehensive hospital admission and death
records, making it unlikely that significant numbers of
patients have been excluded from our sample. The lar-
gest weakness – which is common to the study of CUP
– is that it is based on a diagnosis of exclusion rather
than confirmation and thus a product of the investiga-
tions that are deemed appropriate for any individual.
Further research may be possible into investigations
made prior to diagnosis using Scottish Morbidity Re-
cords (hospitalisation records), which include up to four
paired Office of Population Censuses and Surveys ver-
sion 4 operations and procedures codes. It would also be
potentially possible to study prior and concurrent co-
morbidities which may influence what investigations
and/or treatments might be tolerated by patients, as well
as outcome.
Conclusions
Cancers of Unknown Primary have poor outcomes and
the opportunities to better identify and manage such pa-
tients may be limited because of patients’ short survival
after hospital admission. Supportive and palliative care
may therefore be key contributions that specialist CUP
teams can offer patients. For those patients who present
with more favourable disease, however, early effective
treatment is a priority. Further research on investiga-
tions prior to diagnosis may help to inform more effi-
cient diagnostic pathways that could benefit patients in
either prognostic group.
Table 4 Multivariate analysis of survival of patients diagnosed
with cancer of unknown primary during hospital admission,
1998–2011, West of Scotland, N = 5397
HR (95% confidence interval) P
Morphology
Adenocarcinoma 1
SCC 0.89 (0.73, 1.07) 0.216
NoS 1.43 (1.34, 1.53) <0.001
Other 0.66 (0.56, 0.79) <0.001
ICD10_site
C77 1
C78 1.79 (1.50, 2.14) <0.001
C79 1.10 (0.91, 1.32) 0.32
C80 1.79 (1.50, 2.14) <0.001
Type of admission
Elective 1
Emergency 1.63 (1.49, 1.79) <0.001
Age_group
< 60 year 1
60–69 years 1.32 (1.19, 1.47) <0.001
70–79 years 1.47 (1.34, 1.62) <0.001
> = 80 year 1.44 (1.30, 1.59) <0.001
Gender
Male 1
Female 0.89 (0.84, 0.94) <0.001
Specialty of admission
Geriatric medicine 1
Medicine 0.89 (0.82, 0.98) 0.017
Surgery 0.82 (0.75, 0.91) <0.001
Other 0.78 (0.64, 0.95) 0.011
ICD10_site International Classification of Diseases, 10th Revision, anatomical
site, SCC squamous cell carcinoma, HR hazard ratio, C77 secondary and
unspecified malignant neoplasm of lymph nodes, C78 secondary malignant
neoplasm of respiratory and digestive organs, C79 secondary malignant
neoplasm of other sites, C80 malignant neoplasm without specification of site,
NoS not otherwise specified
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